QB3@953, a full-service San Francisco incubator for life science startups created by QB3, a University of California research institute and biotech accelerator, has inked an agreement with GlaxoSmithKline to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement augments DPAc’s direct outreach to universities and institutions as well as its Discovery Fast Track program.
QB3@953 will work closely with GSK to identify innovators who are exploring targets with therapeutic potential and a defined clinical hypothesis. QB3@953 also will help facilitate collaborations between those researchers and GSK. The new agreement combines the resources and capabilities of GSK with the equipment, lab space and services available at QB3@953 to give the scientists what they need to advance their research toward new medicines.
“This is about finding innovators with great biology and connecting them with GSK’s tremendous drug discovery and development capabilities,” said Douglas Crawford, Ph.D., associate director of QB3 and founder of QB3@953.